La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Sequana Medical Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Ian Crosbie

Amministratore delegato

€440.6k

Compenso totale

Percentuale dello stipendio del CEO	96.5%
Mandato del CEO	8.8yrs
Proprietà del CEO	n/a
Durata media del management	5.5yrs
Durata media del Consiglio di amministrazione	5.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Ian Crosbie rispetto agli utili di Sequana Medical?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-€27m
Mar 31 2024	n/a	n/a	-€30m
Dec 31 2023	€441k	€425k	-€33m
Sep 30 2023	n/a	n/a	-€32m
Jun 30 2023	n/a	n/a	-€32m
Mar 31 2023	n/a	n/a	-€32m
Dec 31 2022	€464k	€449k	-€31m
Sep 30 2022	n/a	n/a	-€29m
Jun 30 2022	n/a	n/a	-€27m
Mar 31 2022	n/a	n/a	-€25m
Dec 31 2021	€417k	n/a	-€24m

Compensazione vs Mercato: La retribuzione totale di Ian ($USD 488.38K ) è circa la media per le aziende di dimensioni simili nel mercato Belgian ($USD 543.88K ).

Compensazione vs guadagni: La retribuzione di Ian è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Ian Crosbie

8.8yrs

Mandato

€440,569

Compensazione

Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV since 2016 and serves as its Director since 2019. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Ian Crosbie	CEO & Executive Director	8.8yrs	€440.57k	Nessun dato
Kirsten Van Bockstaele	Chief Financial Officer	no data	€355.98k	Nessun dato
Lies Vanneste	Director of Investor Relations	5.5yrs	Nessun dato	Nessun dato
Martijn Blom	Chief Commercial Officer	no data	Nessun dato	Nessun dato
Oliver Godje	Chief Medical Officer	4.4yrs	Nessun dato	Nessun dato

5.5yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di SEQUA è esperto e expertise (durata media dell'incarico 5.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ian Crosbie	CEO & Executive Director	5.7yrs	€440.57k	Nessun dato
Erik Amble	Observer	2.2yrs	Nessun dato	0.045% € 13.2k
Wim Ottevaere	Independent Non-Executive Director	5.7yrs	€52.50k	0.057% € 16.7k
James Udelson	Heart Failure Scientific Advisor	4yrs	Nessun dato	Nessun dato
Rudy Dekeyser	Non-Executive Director	no data	Nessun dato	Nessun dato
Maria Costanzo	Scientific Advisor	5.1yrs	Nessun dato	Nessun dato
Pierre Chauvineau	Independent Chairman	5.7yrs	€71.50k	0.019% € 5.5k
Javed Butler	Scientific Advisor	5.1yrs	Nessun dato	Nessun dato
Jeffrey Testani	Scientific Advisor	5.1yrs	Nessun dato	Nessun dato
W.H. Tang	Scientific Advisor	5.1yrs	Nessun dato	Nessun dato
Jackie Fielding	Independent Non-Executive Director	3.1yrs	€49.00k	Nessun dato
G. Felker	Heart Failure Scientific Advisor	4yrs	Nessun dato	Nessun dato

5.1yrs

Durata media

65yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SEQUA sono considerati esperti (durata media dell'incarico 4.9 anni).

Sequana Medical Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Sequana Medical NV, Annual General Meeting, May 23, 2024

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

High number of new directors

Sequana Medical NV Announces Board Changes

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Recent updates

First half 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Shareholder dilution

Sequana Medical Announces Data on Alfapump® Safety and Quality of Life to Be Presented At EASL Congress 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sequana Medical NV to Report First Half, 2024 Results on Sep 19, 2024

Sequana Medical NV to Report First Half, 2024 Results on Sep 12, 2024

Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure

No longer forecast to breakeven

New minor risk - Financial data availability

Sequana Medical NV has filed a Follow-on Equity Offering in the amount of €12 million.

Price target decreased by 26% to €7.63

Sequana Medical NV, Annual General Meeting, May 23, 2024

Forecast to breakeven in 2026

New minor risk - Market cap size

Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure

Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director

Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome

Forecast to breakeven in 2024

First half 2023 earnings released: €0.65 loss per share (vs €0.68 loss in 1H 2022)

New major risk - Financial position

Sequana Medical NV to Report Q2, 2023 Results on Sep 14, 2023

Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure

Forecast to breakeven in 2024

Sequana Medical NV Announces Completion of 1,000th Alfapump Implant

Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director

Price target decreased by 22% to €12.50

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sequana Medical Announces Successful Completion of Pre-Clinical Studies with its Second-Generation DSR Product for Congestive Heart Failure

Price target increased to €16.00

Sequana Medical NV Announces Positive Top-Line Results from SAHARA Ph. 2a Study of DSR 1.0 in Diuretic-Resistant Heart Failure Patients with Persistent Congestion and First Patient Dosed Successfully with DSR 2.0 in YUKON

High number of new directors

Sequana Medical NV Announces Positive Top-Line Results from the North American Pivotal POSEIDON study of the alfapump

First half 2022 earnings released: €0.68 loss per share (vs €0.66 loss in 1H 2021)

Sequana Medical NV to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Sequana Medical NV Announces Board Changes

Price target increased to €13.75

Sequana Medical NV Appoints Doug Kohrs as an Independent Non-Executive Director of the Company

Sequana Medical Completes Enrollment in Phase 2a SAHARA I DSR, Reports Disease-Modifying Profile for Short Term DSR

Price target decreased to €11.75

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Sequana Medical Announces the Completion of Alfapump Implantations in Poseidon, the North American Pivotal Alfapump Study

Sequana Medical NV Receives Certification Under Mdr, the New European Medical Device Regulation

Sequana Medical Announces Positive Interim Results of SAHARA DESERT

First half 2021 earnings released: €0.66 loss per share (vs €0.62 loss in 1H 2020)

Independent Non-Executive Director Jason Hannon has left the company

Sequana Medical’s Results from RED DESERT Alfapump DSR® Study Presented as One of the Highlights At Heart Failure 2021 Online Congress

Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019)

Sequana Medical Announces Positive Results From Second Interim Analysis of North American Pivotal alfapump® Study (POSEIDON)

Sequana Medical Announces First Patient Enrolled in SAHARA DESERT

Sequana Medical NV Announces Positive Top-Line Results from the Red Desert Study with Repeated Dose Alfapump DSR® (Direct Sodium Removal) Therapy in Diuretic-Resistant Heart Failure Patients

Health Check: How Prudently Does Sequana Medical (EBR:SEQUA) Use Debt?

Full year 2020 earnings released: €1.25 loss per share (vs €1.22 loss in FY 2019)

Sequana Medical NV, Annual General Meeting, May 27, 2021

Price target lowered to €13.00

Did Sequana Medical's (EBR:SEQUA) Share Price Deserve to Gain 51%?

New 90-day high: €7.96

Do Institutions Own Sequana Medical NV (EBR:SEQUA) Shares?

Sequana Medical Announces Positive Interim Data from North American Pivotal Alfapump® Study (Poseidon)

New 90-day high: €7.00

Sequana Medical NV Announces Scientific Advisors Appointments

Sequana Medical NV to Report Fiscal Year 2020 Results on Mar 17, 2021

First half earnings released

New 90-day low - €6.02

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione